Vertex Reports Positive Results
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) reported positive results in a midstage clinical trial of its cystic fibrosis treatment VX-770 last week. Shares of the pharmaceutcal leaped $5.23 to close at $23.89.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here